Nemes Rush Group’s BioLineRX BLRX Stock Holding History

Nemes Rush Group’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$780	Hold	250	–	–	﹤0.01%	879
2026 Q1	$575	Hold	250	–	–	﹤0.01%	870
2025 Q4	$693	Hold	250	–	–	﹤0.01%	852
2025 Q3	$945	Hold	250	–	–	﹤0.01%	638
2025 Q2	$1.14K	Sell	250 -50	-17%	-$185	﹤0.01%	644
2025 Q1	$888	Hold	300	–	–	﹤0.01%	653
2024 Q4	$2.57K	Hold	300	–	–	﹤0.01%	594
2024 Q3	$13.4K	Hold	300	–	–	﹤0.01%	379
2024 Q2	$6.84K	Hold	300	–	–	﹤0.01%	446
2024 Q1	$13.4K	Hold	300	–	–	﹤0.01%	414
2023 Q4	$18.8K	Hold	300	–	–	﹤0.01%	353
2023 Q3	$21.8K	Hold	300	–	–	﹤0.01%	331
2023 Q2	$19.1K	Buy	+300	New	+$16.6K	﹤0.01%	368

Other funds holding BLRX

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

BCV

Banque Cantonale Vaudoise Lausanne, Switzerland $722M AUM 30.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Nemes Rush Group's BLRX Position: Q2 2026 in Review

Nemes Rush Group held its BioLineRX (BLRX) position steady in Q2 2026 at 250 shares worth $780. The position accounts for ﹤0.01% of the portfolio, ranked #879.

Nemes Rush Group first reported a position in BLRX in Q2 2023 and has held it in 13 quarters since. The position peaked at $21.8K in Q3 2023. 14 funds tracked by Wall St. Rank hold BLRX as of Q2 2026.

Nemes Rush Group held 250 shares of BioLineRX worth $780 as of Q2 2026.
Nemes Rush Group left its BioLineRX share count unchanged in Q2 2026.
BioLineRX made up ﹤0.01% of Nemes Rush Group's portfolio in Q2 2026, its #879 holding.
Nemes Rush Group first reported a position in BioLineRX in Q2 2023 and has held it in 13 quarters since.
Nemes Rush Group's BioLineRX position peaked at $21.8K in Q3 2023.
14 funds tracked by Wall St. Rank held BioLineRX as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.